As required under Regulation 33(3) of SEBI(LODR) , Regulations , 2015 we are enclosing herewith the Unaudited Financial Results for Quarter Ended on 30-6-2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Colinz Laboratories, a small Mumbai-based pharmaceutical formulations maker, approved its unaudited results for the quarter ended 30 June 2025 along with a clean limited-review report from statutory auditor Vora & Associates. Revenue from operations stood at Rs. 156.61 lakhs, down from Rs. 174.66 lakhs in the same quarter last year – a roughly 10% YoY decline. Total income came in at Rs. 164.13 lakhs (vs Rs. 181.39 lakhs). Profit after tax was Rs. 11.92 lakhs versus Rs. 13.72 lakhs in Q1 FY25, also lower, translating to basic EPS of Rs. 0.47 (vs Rs. 0.54). For the full FY25, the company had reported revenue of Rs. 652.77 lakhs, PAT of Rs. 49.66 lakhs and EPS of Rs. 1.97. The Board also cleared the Director's Report and other annual disclosure documents, approved the appointment of Mr Swapnil Madiyar as Non-Executive Director, reappointed Mr N.K. Menon as Whole Time Director & CEO for one year, appointed CA Ajay Ramsevak Sharma as Internal Auditor and M/s. Sanjay Dholakia & Associates as Secretarial Auditor, and fixed the 39th AGM on 30 September 2025 via video conferencing.
Both top line and bottom line contracted year-on-year in Q1, which is a mildly negative signal for shareholders given the already small revenue base. However, the company's overall scale remains very modest (sub-Rs. 7 crore annual revenue) so the swing may not move the needle materially on this thinly-traded counter. No dividend or major capital action was announced.